Sirona Biochem CEO Howard Verrico said the company is charged up to succeed in both the cosmetic and therapeutic spaces.
Sirona Biochem CEO: Unique Opportunity for Global Success in the Cosmetic and Therapeutic Spaceswww.youtube.com
Sirona Biochem (TSXV:SBM) has revealed positive results from a clinical study on its active ingredient TFC-1067. Sirona Biochem CEO Howard Verrico said the company is charged up to succeed in both the cosmetic and therapeutic spaces.
“We apply our technology to improve the efficiency of molecules, fuse their efficacy from reduced toxicity, and just make a better compound. So there are opportunities to come up in multiple fields leading us into the cosmetic space and also into the therapeutic space. The cosmetic space is a much shorter path to commercialization, while therapeutics is a more traditional, but very rewarding path. So we take advantage of both opportunities,” said Dr. Verrico.
TFC-1067 is a synthetic active and a part of the arbutin family. Sirona’s proprietary platform technology advances this ingredient to correct dark spots and other medical conditions such as hyperpigmentation, melasma, vitiligo and rosacea.
“We’ve come up with a molecule which we believe is an industry leader because it is both safe and effective. It’s an enormous breakthrough so we’re bringing an opportunity for people who have dark spots or uneven skin tone to safely treat those and do so effectively.”
In March 2021, Sirona Biochem launched its first commercial product containing TFC-1067, which debuted as the active ingredient in New Rodan + Fields’ REVERSE Targeted Dark Spot Corrector.
“We conducted further analysis with one of the top large pharmaceutical companies in the world. And we had a very successful clinical trial and we’re entering a phase to process a licensing deal. Our goal is to develop a global licensing with this partner and bring this compound to global success.”
Watch the full interview of Sirona Biochem CEO Dr. Howard Verrico above.
This interview is sponsored by Sirona Biochem (TSXV:SBM). This interview provides information which was sourced by the Investing News Network (INN) and approved by Sirona Biochem in order to help investors learn more about the company. Sirona Biochem is a client of INN. The company’s campaign fees pay for INN to create and update this interview.
INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.
The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with Sirona Biochem and seek advice from a qualified investment advisor.